Extracellular signalregulated kinase 5 promotes acute cellular and systemic inflammation

Science Signaling

Volumn 8, Issue 391, 2015, Pages ra86-

  Wilhelmsen, Kevin ^a   Xu, Fengyun ^a   Farrar, Katherine ^b   Tran, Alphonso ^a   Khakpour, Samira ^b   Sundar, Shirin ^a   Prakash, Arun ^a   Wang, Jinhua ^c   Gray, Nathanael S ^c   Hellman, Judith ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; IL1B PROTEIN, HUMAN; IL1B PROTEIN, MOUSE; MAPK7 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; TLR2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; STAPHYLOCOCCUS AUREUS; VASCULAR ENDOTHELIUM; AGONISTS; ANIMAL; IMMUNOLOGY; MALE; PATHOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-1BETA; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 7; MONOCYTES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940371897     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa3206     Document Type: Article

References (129)

1. K. Ley, C. Laudanna, M. I. Cybulsky, S. Nourshargh, Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007).
2. R. Medzhito v, Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
3. A. Zarbock, K. Ley, Mechanisms and consequences of neutrophil interaction with the endothelium. Am. J. Pathol. 172, 1-7 (2008).
4. A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate immune system. Science 327, 291-295 (2010).
5. S. Hirsiger, H.-P. Simmen, C. M. L. Werner, G. A. Wanner, D. Rittirsch, Danger signals activating the immune response after trauma. Mediators Inflamm. 2012, 1-10 (2012).
6. U. Jaffer, R. G. Wade, T. Gourlay, Cytokines in the systemic inflammatory response syndrome: A review. HSR Proc. Intensive Care Cardiovasc. Anesth. 2, 161-175 (2010).
7. A. Lenz, G. A. Franklin, W. G. Cheadle, Systemic inflammation after trauma. Injury 38, 1336-1345 (2007).
8. D. Rittirsch, M. A. Flierl, P. A. Ward, Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8, 776-787 (2008).
9. M. Schouten, W. J. Wiersinga, M. Levi, T. Van Der Poll, Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545 (2008).
10. M. Levi, E. De Jonge, T. Van Der Poll, Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis 16, 43-47 (2003).
11. N. Semeraro, C. T. Ammollo, F. Semeraro, M. Colucci, Sepsis, thrombosis and organ dysfunction. Thromb. Res. 129, 290-295 (2012).
12. H. C. Kwaan, Microvascular thrombosis: A serious and deadly pathologic process in multiple diseases. Semin. Thromb. Hemost. 37, 961-978 (2011).
13. R. M. Durham, J. J. Moran, J. E. Mazuski, M. J. Shapiro, A. E. Baue, L. M. Flint, Multiple organ failure in trauma patients. J. Trauma 55, 608-616 (2003).
14. G. S. Martin, D. M. Mannino, S. Eaton, M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
15. V. D. Mayr,M.W. Dünser, V. Greil, S. Jochberger, G. Luckner, H. Ulmer, B. E. Friesenecker, J. Takala, W. R. Hasibeder, Causes of death and determinants of outcome in critically ill patients. Crit. Care 10, R154 (2006).
16. Y. Sakr, S. M. Lobo, R. P. Moreno, H. Gerlach, V. M. Ranieri, A. Michalopoulos, J.-L. Vincent; SOAP Investigators, Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit. Care 16, R222 (2012).
17. M. J. Hickey, P. Kubes, Intr avascular immunity: The host-pathogen encounter in blood vessels. Nat. Rev. Immunol. 9, 364-375 (2009).
18. B. McDonald, K. Pittman, G. B. Menezes, S. A. Hirota, I. Slaba, C. C. M. Waterhouse, P. L. Beck, D. A. Muruve, P. Kubes, Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366 (2010).
19. G. Y. Chen, G. Nuñez, Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
20. D. Rittirsch H. Redl M. Huber-Lang Role of complement in multiorgan failure. Clin. Dev. Immunol. 2012 962927 2012).
21. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
22. H.-S. Shin, F. Xu, A.Bagchi, E. Herrup, A. Prakash, C. Valentine,H. Kulkarni,K.Wilhelmsen, S.Warren, J. Hellman, Bacterial lipoprotein TLR2 agonists broadly modulate endothelial function and coagulation pathways in vit ro and in vivo. J. Immunol. 186, 1119-1130 (2011).
23. K. Wilhelmsen, K. R. Mesa, J. Lucero, F. Xu, J. Hellman, ERK5 protein promotes, whereas MEK1 protein differentially regulates, the Toll-like receptor 2 proteindependent activation of human endothelial cells and monocytes. J. Biol. Chem. 287, 26478-26494 (2012).
24. T. Collins, M. A. Read, A. S. Neish, M. Z. Whitley, D. Tha nos, T. Maniatis, Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J. 9, 899-909 (1995).
25. K. Wilhelmsen, K. R. Mesa, A. Prakash, F. Xu, J. Hellman, Activation of endothelial TLR2 by bacterial lipoprotein upregulates proteins specific for the neutrophil response. Innate Immun. 18, 602-616 (2012).
26. T. Iwaki, T. Ur ano, K. Umemura, PAI-1, progress in understanding the clinical problem and its aetiology. Br. J. Haematol. 157, 291-298 (2012).
27. S. Gando, Role of fibrinolysis in sepsis. Semin. Thromb. Hemost. 39, 392-399 (2013).
28. R. M. Mesters, N. Florke, H. Ostermann, J. Kienast, Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb. Haemost. 75, 902-907 (1996).
29. C. D. Buckley, D. W. Gilroy, C. N. Serhan, Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315-327 (2014).
30. J. S. C. Arthur, S. C. Ley, Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13, 679-692 (2013).
31. M. Cargnello, P. P. Roux, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50-83 (2011).
32. S. Vallabhapurapu, M. Karin, Regulation and function of NF-kB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733 (2009).
33. C. Widmann, S. Gibson, M. B. J arpe, G. L. Johnson, Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 79, 143-180 (1999).
34. P. Cohen, Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21, 317-324 (2009).
35. G. Zhou, Z. Q. Bao, J. E. Dixon, Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270, 12665-12669 (1995).
36. J. M. English, C. A. Vanderbilt, S. Xu, S. Marcus, M. H. Cobb, Isolation of MEK5 and differential expression of alternatively spliced forms. J. Biol. Chem. 270, 28897-28902 (1995).
37. J. D. Lee, R. J. Ulevitch, J. H. Han, Primary structure of BMK1: A new mammalian map kinase. Biochem. Biophys. Res. Commun. 213, 715-724 (1995).
38. G. N. Nithianandarajah-Jones, B. Wilm, C. E. P. Goldring, J. Müller, M. J. Cross, ERK5: Structure, regulation and function. Cell. Signal. 24, 2187-2196 (2012).
39. N. Mody, D. G. Campbell, N. Morrice, M. Peggie, P. Cohen, An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem. J. 372, 5 67-575 (2003).
40. H. Morimoto, K. Kondoh, S. Nishimoto, K. Terasawa, E. Nishida, Activation of a Cterminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol. Chem. 282, 354 49-35456 (2007).
41. M. Hayashi, R. I. Tapping, T.-H. Chao, J.-F. Lo, C. C. King, Y. Yang, J.-D. Lee, BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J. Biol. Chem. 276, 8631-8634 (2001).
42. S. J. Cameron, S. Malik, M. Akaike, N. Lerner-Marmarosh, C. Yan, J.-D. Lee, J.-i. Abe, J. Yang, Regulation of ep idermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase 1/ERK5 but not ERK1/2 kinase activation. J. Biol. Chem. 278, 18682-18688 (2003).
43. M. Kim, S. Kim, J. H. Lim, C. Lee, H. C. Choi, C. H. Woo, Laminar flow activation of ERK5 protein in vascular endothelium leads to atheroprotective effect via NF-E2-related factor 2 (Nrf2) activation. J. Biol. C hem. 287, 40722-40731 (2012).
44. P. R. Clark, T. J. Jensen, M. S. Kluger, M. Morelock, A. Hanidu, Z. Qi, R. J. Tatake, J. S. Pober, MEK5 is activated by shear stress, activates ERK5 and induces KLF4 to modulate TNF responses in human dermal microvascular endothelial cells. Microcirculation 18, 102-117 (2011).
45. N. Ohnesorge, D. Viemann, N. Schmidt, T. Czymai, D. Spiering, M. Schmolke, S. Ludwig, J. Roth, M. Goebeler, M. Schmidt, Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Krüppel-like factor 4 (KLF4). J. Biol. Chem. 285, 26199-2621 0 (2010).
46. T. Sasaki, H. Kojima, R. Kishimoto, A. Ikeda, H. Kunimoto, K. Nakajima, Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. Mol. Cel l 24, 63-75 (2006).
47. C.-H.Woo, M. P. Massett, T. Shishido, S. Itoh, B. Ding, C. McClain, W. Che, S. R. Vulapalli, C. Yan, J.-i. Abe, ERK5 activation inhibits inflammatory r esponses via peroxisome proliferator-activated receptor d (PPARd) stimulation. J. Biol. Chem. 281, 32164-32174 (2006).
48. M. Akaike, W. Che, N.-L. Marmarosh, S. Ohta, M. Osawa, B. Ding, B. C. Berk, C. Yan, J.-i. Abe, The hinge-helix 1 region of peroxisome proliferator-activated receptor g1 (PPARg1) mediates interaction with extracellular signal-regulated kinase 5 and PPARg1 transcriptional activation: Involvement in flow-induced PPARg activation in endothelial cells. Mol. Cell. Biol. 24, 8691-8704 (2004).
49. K. Terasawa, K. Okazaki, E. Nishida, Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells 8, 263-273 (2003).
50. Y. Kato, M. Zhao, A. Morikawa, T. Sugiyama, D. Chakravortty, N. Koide, T. Yoshida, R. I. Tapping, Y. Yang, T. Yokochi, J.-D. Lee, Big mitogen-activated kinase reg ulates multiple members of the MEF2 protein family. J. Biol. Chem. 275, 18534-18540 (2000).
51. C. C. Yang, O. I. Ornatsky, J. C. McDermott, T. F. Cruz, C. A. Prody, Interaction of myocyte enhancer fac tor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res. 26, 4771-4777 (1998).
52. J. M. English, G. Pearson, R. Baer, M. H. Cobb, Identification of substrates and regulator s of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J. Biol. Chem. 273, 3854-3860 (1998).
53. Y. Kato, V. V. Kravchenko, R. I. Tapping, J. Han, R. J. Ulevitch, J.-D. Lee, BMK1/ERK5 regu lates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16, 7054-7066 (1997).
54. M. Buschbeck, A. Ullrich, The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J. Biol. Chem. 280, 2659-2667 (2005).
55. F. A. Iñesta-Vaquera, D. G. Campbell, J. S. C. Arthur, A. Cuenda, ERK5 pathway regulates the phosphorylation of tumour suppressor hDlg during mitosis. Biochem. Biophys. Res. Commun. 399, 84-90 (2010).
56. A. Ranganathan, G. W. Pearson, C. A. Chrestensen, T. W. Sturgill, M. H. Cobb, The MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch. Biochem. Biophys. 449, 8-16 (2006).
57. B.-e. Xu, S. Stippec, L. Lenertz, B.-H. Lee, W. Zhang, Y.-K. Lee, M. H. Cobb, WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J. Biol. Chem. 279, 7826-7831 (2004).
58. Q. Zheng, G. Yin, C. Yan, M. Cavet, B. C. Berk, 14-3-3b binds to big mitogen-activated protein kinase 1 (BMK1/ERK5) and regulates BMK1 function. J. Biol. Chem. 279, 8787-8791 (2004).
59. W. Sun, X.Wei, K. Kesa van, T. P. Garrington, R. Fan, J. Mei, S.M. Anderson, E.W. Gelfand, G. L. Johnson, MEK kinase 2 and the adaptor protein Lad regulate extracellular signalregulated kinase 5 activation by epidermal growth factor via Src. Mol. Ce ll. Biol. 23, 2298-2308 (2003).
60. W. Sun, K. Kesavan, B. C. Schaefer, T. P. Garrington, M. Ware, N. L. Johnson, E. W. Gelfand, G. L. Johnson, MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J. Biol. Chem. 276, 5093-5100 (2001).
61. S. J. Sohn, B. K. Sarvis, D. Cado, A. Winoto, ERK5 MAPK regulates embryonic angiogenesis and acts as a hyp oxia-sensitive repressor of vascular endothelial growth factor expression. J. Biol. Chem. 277, 43344-43351 (2002).
62. L. Yan, J. Carr, P. R. Ashby, V. Murry-Tait, C. Thompson, J. S. C. Arthur, Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev. Biol. 3, 11 (2003).
63. C. P. Regan W. Li D. M. Boucher S. Spatz M. S. Su K. Kuida Erk5 null m ice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc. Natl. Acad. Sci. U.S.A. 99 9248-9253 2002).
64. M. Hayashi, S.-W. Kim, K. Imanaka-Yoshida, T. Yoshida, E. D. A bel, B. Eliceiri, Y. Yang, R. J. Ulevitch, J.-D. Lee, Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J. Clin. Invest. 113, 1138-1148 (2004).
65. O. L. Roberts, K. Holmes, J. Müller, D. A. E. Cross, M. J. Cross, ERK5 and the regulation of endothelial cell function. Biochem. Soc. Trans. 37, 1254-1259 (2009).
66. Y.W. Pan, J. Zou ,W.Wang, H. Sakagami, M. G. Garelick, G. Abel, C. T. Kuo, D. R. Storm, Z. Xia, Inducible and conditional deletion of extracellular signal-regulated kinase 5 disrupts adult hippocampal neurogenesis. J. Biol. Chem. 287, 23306-23317 (2012).
67. Y. W. Pan, C. T. Kuo, D. R. Storm, Z. Xia, Inducible and targeted deletion of the ERK5 MAP kinase in adult neurogenic regions impairs adult neurogenesis in the olfactory bulb and several forms of olfactory behavior. PLOS One 8, e49622 (2013).
68. O. Ananieva, A. Macdonald, X. Wang, C. E. McCoy, J. McIlrath, C. Tournier, J. S. C. Arthur, ERK5 regulation in naï ve T-cell activation and survival. Eur. J. Immunol. 38, 2534-2547 (2008).
69. T. Li, Y.-W. Pan, W. Wang, G. Abel, J. Zou, L. Xu, D. R. Storm, Z. Xia, Targeted deletion of the ERK5 MAP kinase impairs neuronal differentiation, migration, and survival during adult neurogenesis in the olfactory bulb. PLOS One 8, e61948 (2013).
70. J. Zou, Y.-W. Pan, Z. Wang, S.-Y. Chang, W. Wang, X. Wang, C. Tournier, D. R. Storm, Z. Xia, Targeted deletion of ERK5 MAP kinase in the developing nervous system impairs development of GABAergic interneurons in the main olfactory bulb and behavioral discrimination between structurally si milar odorants. J. Neurosci. 32, 4118-4132 (2012).
71. W. Wang, Y.-W. Pan, T. Wietecha, J. Zou, G. M. Abel, C. T. Kuo, Z. Xia, Extracellular signal-regulated kinase 5 (ERK5) mediates prolactin-stimulated adult neurogenesis in the subventricular zone and olfactory bulb. J. Bi ol. Chem. 288, 2623-2631 (2013).
72. R. J. Tatake, M. M. O'Neill, C. A. Kennedy, A. L. Wayne, S. Jakes, D. Wu, S. Z. Kugler Jr., M. A. Kashem, P. Kaplita, R. J. Snow, Ide ntification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem. Biophys. Res. Commun. 377, 120-125 (2008).
73. P. T. Flaherty, I. Chopra, P. Jain, D. Monlish, J. Cavanaugh, Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway. Bioorg. Med. Chem. 18, 8054-8060 (2010).
74. P. T. Flaherty, I. Chopra, P. Jain, S. Yi, E. Allen, J. Cavanaugh, Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway. Bioorg. Med. Chem. Lett. 20, 2892-2896 (2010).
75. Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M. P. Patricelli, J. R. Yates III, N. S. Gray, J. D. Lee, Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 1 8, 258-267 (2010).
76. S. Á lvarez-Fernández, M. J. Ortiz-Ruiz, T. Parrott, S. Zaknoen, E. M. Ocio, J. San Miguel, F. J. Burrows, A. Esparís-Ogando, A. Pandiella, Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin. Cancer Res. 19, 2677-2687 (2013).
77. Q. Yang, J.-D. Lee, Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin. Cancer Res. 17, 3527-3532 (2011).
78. J. C. Montero, A. Ocaña, M. Abad, M. J. Ortiz-Ruiz, A. Pandiella, A. Esparís-Ogando, Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential t herapeutic target. PLOS One 4, e5565 (2009).
79. P. B. Mehta, B. L. Jenkins, L. McCarthy, L. Thilak, C. N. Robson, D. E. Neal, H. Y. Leung, MEK5 overexpression is associated with meta static prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22, 1381-1389 (2003).
80. C. Sticht, K. Freier, K. Knöpfle, C. Flechtenmacher, S. Pungs, C. Hofele , M. Hahn, S. Joos, P. Lichter, Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia 10, 462-470 (2008).
81. C. B. Weldon, A. B. Scandurro, K. W. Rolfe, J. L. Clayton, S. Elliott, N. N. Butler, L. I. Melnik, J. Alam, J. A. McLachlan, B. M. Jaffe, B. S. Beckman, M. E. Burow, Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132, 293-301 (2002).
82. A. Esparís-Ogando, E. Díaz-Rodríguez, J. C. Monter o, L. Yuste, P. Crespo, A. Pandiella, Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22, 270-285 (2002).
83. S. Nagel, C. Burek, L. Venturini, M. Scherr, H. Quentmeier, C. Meyer, A. Rosenwald, H. G. Drexler, R. A. F. MacLeod, Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109, 3015-3023 (2007).
84. M. E. Ramos-Nino S. R. Blumen T. Sabo-Attwood H. Pass M. Carbone J. R. Testa D. A. Altomare B. T. Mossman HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am. J. Respir. Cell Mol. Biol. 38 209-217(2008).
85. J. Garaude, S. Cherni, S. Kaminski, E. Delepine, C. Chable-Bessia,M. Benkirane, J. Borges, A. Pandiella, M. A. Iñiguez, M. Fresno, R. A. Hipskind, M. Villalba, ERK5 activates NF-kB in leukemic T cells and is essential for their growth in vivo. J. Immunol. 177, 7607-7617 (2006).
86. M. Hayashi, C. Fearns, B. Eliceiri, Y. Yang, J.-D. Lee, Big mitogen-activated protein kinase 1/extr acellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res. 65, 7699-7706 (2005).
87. S. R. C. McCracken, A. Ramsay, R. Heer, M. E. Mathers, B. L. Jenkins, J. Edwards, C. N. Robson, R. Marquez, P. Cohen, H. Y. Leung, Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 27, 2978-2988 (2008).
88. A. K. Ramsay, S. R. C. McCracken, M. Soofi, J. Fleming, A. X. Yu, I. Ahmad, R. Morland, L. Machesky, C. Nixon, D. R. Edwards, R. K. Nuttall, M. Seywright, R. Marquez, E. Keller, H. Y. Leun g, ERK5 signalling in prostate cancer promotes an invasive phenotype. Br. J. Cancer 104, 664-672 (2011).
89. K. Wu, S. Tian, H. Zhou, Y. Wu, Statins protect human endothelial cells from TNFinduced inflammation via ERK5 activation. Biochem. Pharmacol. 85, 1753-1760 (2013).
90. K.-S. Heo, E. Chang, N.-T. Le, H. Cushman, E. T. H. Yeh, K. Fujiwara, J.-i. Abe, De-SU MOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ. Res. 112, 911-923 (2013).
91. L. Li, R. J. Tatake, K. Natarajan, Y. Taba, G. Garin, C. Tai, E. Leung, J. Surapisitchat, M. Yoshizumi, C. Yan, J.-i. Abe, B. C. Berk, Fluid shear stress inhibits TNF-mediated JNK activation via MEK5-BMK1 in endothe lial cells. Biochem. Biophys. Res. Commun. 370, 159-163 (2008).
92. N. T. Le, Y. Takei, Y. Izawa-Ishizawa, K. S. Heo, H. Lee, A. V. Smrcka, B. L. Miller, K. A. Ko, S. Ture, C. Morrel l, K. Fujiwara, M. Akaike, J. I. Abe, Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J. Immunol. 193, 3803-3815 (2014).
93. D. Z. Mackesy, M. L. Goalstone, Extracellular signal-regulated kinase-5: Novel mediator of insulin and tumor necrosis factor a-stimulated vascular cell adhesion mol ecule-1 expression in vascular cells. J. Diabetes 6, 595-602 (2014).
94. G. C. Luerman, C. Nguyen, H. Samaroo, P. Loos, H. Xi, A. Hurtado-Lorenzo, E. Needle, G. Stephen Noell, P. Galatsis, J. Dunlop, K. F. Geoghegan, W. D. Hirst, Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J. Neurochem. 128, 56 1-576 (2014).
95. J.-L. Sun, C. Xiao, B. Lu, J. Zhang, X.-z. Yuan, W. Chen, L.-N. Yu, F.-J. Zhang, G. Chen, M. Yan, CX3CL1/CX3CR1 regulates nerve injury-induced pain hypersensitivity through the ERK5 signaling pathway. J. Neurosci. Res. 91, 545-553 (2013).
96. S. Kim, J. H. Lim, C. H. Woo, ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation. Am. J. Pathol. 183, 1758-1768 (2013).
97. W. Zhu, J. S. Downey , J. Gu, F. Di Padova, H. Gram, J. Han, Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164, 6349-6358 (2000).
98. C. S. Hii, D. S. Anson, M. Costabile, V. Mukaro, K. Dunning, A. Ferrante, Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response. J. Biol. Chem. 279, 49825-49834 (2004).
99. R. Ahmad, P. K. Shihab, S. Jasem, K. Behbehani, FSL-1 induces MMP-9 production through TLR-2 and NF-kB/AP-1 signaling pathways in monocytic THP-1 cells. Cell. Physiol. Biochem. 34, 929-942 (2014).
100. J. M. Elkins, J. Wang, X. Deng, M. J. Pattison, J. S. C. Arthur, T. Erazo, N. Gomez, J. M. Lizcano, N. S. Gray, S. Knapp, X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. J. Med. Chem. 56, 4413-4421 (2013).
101. X. Deng, J. M. Elkins, J. Zhang, Q. Yang, T. Erazo, N. Gomez, H. G. Choi, J. Wang, N. Dzamko, J.-D. Lee, T. Sim, N. Kim, D. R. Alessi, J. M. Lizcano, S. Knapp, N. S. Gray, Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur. J. Med. Chem. 70, 758-767 (2013).
102. G. Glatz, G. Gógl, A. Alexa, A. Reményi, Structural mechanism for the specific assembly and activation of the extracellular signal regulated kinase 5 (ERK5) module. J. Biol. Chem. 288, 8596-8609 (2013).
103. A. Lin, A. Minden, H. Martinetto, F. X. Claret, C. Lange-Carter, F. Mercurio, G. L. Johnson, M. Karin, Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268, 286-290 (1995).
104. K. Wilhelmsen, K. Farrar, J. Hellman, Quantitative in vitro assay to measure neutrophil adhesion to a ctivated primary human microvascular endothelial cells under static conditions. J. Vis. Exp. e50677 (2013).
105. M. C. De Almeida, A. C. Silva, A. Barral, M. Barral Netto, A simple method for human peripheral blood monocyte isolation. Mem. Inst. Oswaldo Cruz 95, 221-223 (2000).
106. S. Pfeiler, S. Massberg, B. Engelmann, Biological basis and pathological relevance of microvascular thrombosis. Thromb. Res. 133 (Suppl.1), S35-S37 (2014).
107. D. De Backer, D. Orbegozo Cortes, K. Donadello, J.-L. Vincent, Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence 5, 73-79 (2014).
108. A. Prakash, K. R. Mesa, K. Wilhelmsen, F. Xu, J. M. Dodd-o, J. Hellman, Alveolar macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion injur y in mice. Anesthesiology 117, 822-835 (2012).
109. T.-H. Chao, M. Hayashi, R. I. Tapping, Y. Kato, J.-D. Lee, MEKK3 directly regulates MEK5 activity as part of the big mitogen-activat ed protein kinase 1 (BMK1) signaling pathway. J. Biol. Chem. 274, 36035-36038 (1999).
110. M. Chiariello, M. J. Marinissen, J. S. Gutkind, Multiple mitogen-activated protein kinase signaling pathways conn ect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol. Cell. Biol. 20, 1747-1758 (2000).
111. M. P. Belich, A. Salmerón, L. H. Johnston, S. C. Ley, TPL-2 kinase regulates the proteolysis of the NF-kB-inhibitory protein NF-kB1 p105. Nature 397, 363-368 (1999).
112. J. M. English, G. Pearson, T. Hockenberry, L. Shivakumar, M. A. White, M. H. Cobb, Contribution of the E RK5/MEK5 pathway to Ras/Raf signaling and growth control. J. Biol. Chem. 274, 31588-31592 (1999).
113. S. Kamakura, T. Moriguchi, E. Nishida, Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274, 265 63-26571 (1999).
114. H. J. Yoon, S.-B. Jeon, I.-H. Kim, E. J. Park, Regulation of TLR2 expression by prostaglandins in brain glia. J. Immunol. 180, 8400-8409 (2008).
115. T.-H. Han, R. Prywes, Regulatory role of MEF2D in serum induction of the c-jun promoter. Mol. Cell. Biol. 15, 2907-2915 (1995).
116. E. Shaulian, M. Karin, AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400 (2001).
117. R. Zenz, R. Eferl, C. Scheinecker, K. Redlich, J. Smolen, H. B. Schonthaler, L. Kenner, E. Tschachler, E. F. Wagner, Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther. 10, 201 (2008).
118. M. Karin, Inflammation-activated protein kinases as targets for drug development. Proc. Am. Thorac. Soc. 2, 386-390; discussion 394-395 (2005).
119. S. J. Sohn, D. Li, L. K. Lee, A. Winoto, Transcriptional regulation of tissue-specific genes by the ERK5 mitogen-activated protein kinase. Mol. Cell. Biol. 2 5, 8553-8566 (2005).
120. J. Zahlten, R. Steinicke, B. Opitz, J. Eitel, P. D. N'Guessan, M. Vinzing, M. Witzenrath, B. Schmeck, S. Hammerschmidt, N. Suttorp, S. Hippenstiel, TLR 2-and nucleotidebinding oligomerization domain 2-dependent Krüppel-like factor 2 expression downregulates NF-kB-related gene expression. J. Immunol. 185, 597-604 (2010).
121. S. SenBanerjee, Z. Lin, G. B. Atkins, D. M. Greif, R. M. Rao, A. Kumar, M. W. Feinberg, Z. Chen, D. I. Simon, F.W. Luscinskas,T. M. Michel, M. A. Gimbrone Jr., G. García-Cardeña, M. K. Jain, KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J. Exp. Med. 199, 1305-1315 (2004).
122. Z. Lin, A. Kumar, S. SenBanerjee, K. Staniszewski, K. Parmar, D. E. Vaughan, M. A. Gimbrone Jr., V. Balasubramanian, G. García-Cardeña, M. K. Jain, Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ. Res. 96, 48-57 (2005).
123. R. Bhattacharya, S. Senbanerjee, Z. Lin, S. Mir, A. Hamik, P. Wang, P. Mukherjee, D. Mukhopadhyay, M. K. Jain, Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848-28851 (2005).
124. R. A. Boon, A. J. G. Horrevoets, Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie 29, 39-43 (2009).
125. A. R. Kinderlerer, F. Ali, M. Johns, E. A. Lidington, V. Leung, J. J. Boyle, S. S. Hamdulay, P. C. Evans, D. O. Haskard, J. C. Mason, KLF2-dependent, shear stress-induced expression of CD59: A novel cytoprotective mechanism against complement-mediated injury in the vasculature. J. Biol. Chem. 283, 14636-14644 (2008).
126. K. M. Parmar, H. B. Larman, G. Dai, Y. Zhang, E. T. Wang, S. N. Moorthy, J. R. Kratz, Z. Lin, M. K. Jain, M. A. Gimbrone Jr., G. García-Cardeña, Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J. Clin. Invest. 116, 49-58 (2006).
127. G. Pearson, J. M. English, M. A. White, M. H. Cobb, ERK5 and ERK2 cooperate to regulate NF-kB and cell transformation. J. Biol. Chem. 276 7927-7931 2001).
128. K. Cude, Y. Wang, H.-J. Choi, S.-L. Hsuan, H. Zhang, C.-Y.Wang, Z. Xia, Regulation of the G2-M cell cycle progression by the ERK5-NFkB signaling pathway. J. Cell Biol. 177, 253-264 (2007).
129. A. E. S. Simões, D. M. Pereira, S. E. Gomes, H. Brito, T. Carvalho, A. French, R. E. Castro, C. J. Steer, S. N. Thibodeau, C. M. P. Rodrigues, P. M. Borralho, Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-kB activation. Cell Death Dis. 6, e1718 (2015).